AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and option-to-license agreement to develop novel...

View the Online Magazine

Launches

Pioneer Group drives AI innovation in healthcare through industry and academic collaboration

Pioneer Group, the life science infrastructure and venture building specialist, has joined forces with Innovate UK, The Medical Research Council (MRC) and AstraZeneca, to...

New SWLP laboratory at Croydon Hospital transforms the diagnostic facility into one of the most advanced and innovative in the UK

South West London Pathology (SWLP) introduces cutting-edge technologies to its laboratories to create one of the most modern, innovative, and efficient clinical blood science...

Amazon Filters launches high-temp vent filter for pharma and biotech

A UK process filter manufacturer has launched an enhanced high-temperature-resistant membrane product aimed at vent applications across the global pharmaceutical and biotechnology markets. Amazon Filters’...

Suppliers Guide

Check out our Suppliers Guide or contact our team and get your company listed

Subscribe

Keep up with what's happening in the industry and subscribe to our weekly newsletter

Events

Get your event seen by potential candidates on the world's leading industry site.

Supply Chain

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15, a biosimilar candidate to Darzalex & Darzalex Faspro in the U.S. and Europe

Dr. Reddy’s Laboratories has entered into a license agreement with Shanghai Henlius Biotech for the commercialization of HLX15, Henlius’ investigational daratumumab biosimilar candidate to...

Er-Kim signs distribution agreement with the MEDICE Health Family for Vafseo in Central & Eastern Europe

Er-Kim, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies, has signed a distribution agreement with the MEDICE...

Er-Kim extends exclusive distribution agreement with Ascendis to expand commercialization of endocrinology portfolio

Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, has extended its exclusive agreement with Danish biopharmaceutical company Ascendis Pharma to commercialize...

Camida wins Pharma Supplier of the Year!

The much-coveted title, Pharma Supplier of the Year, was bestowed upon Camida at the 2024 Pharma Industry Awards. (Wednesday, 30 October / Dublin, Ireland) Camida...

Approvals

BridgeBio’s BEYONTTRA approved by European Commission to treat ATTR-CM

The European Commission has granted marketing authorization in the European Union (EU) for BridgeBio Pharma's acoramidis, under the brand name BEYONTTRA, for the treatment...

U.S. FDA approves SpringWorks Therapeutics’ GOMEKLI for patients with NF1-PN

The U.S. Food and Drug Administration (FDA) has approved SpringWorks Therapeutics' GOMEKLI (mirdametinib), SpringWorks’ MEK inhibitor, for the treatment of adult and pediatric patients...

Manufacturiung

Finance

Research & Development
Latest

AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies

AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...

Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...

FDA orphan drug and rare pediatric disease designations granted to Arbor Biotechnologies’ primary hyperoxaluria type 1 treatment

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare pediatric disease designation (RPDD) to Arbor Biotechnologies' ABO-101 for...

Relmada Therapeutics acquires potential Tourette syndrome therapy from Asarina Pharma

Relmada Therapeutics, a clinical-stage biotechnology company, has acquired Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma, being developed for the potential treatment of...

Vanda Pharmaceuticals and AnaptysBio announce global license agreement for Generalized Pustular Psoriasis treatment

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully...

Appointments